The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience

Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aimed to demonstrate the outcomes of metronomic chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma (LA HNSCC). This was a retrospective study inclu...

Full description

Saved in:
Bibliographic Details
Published in:Biology (Basel, Switzerland) Switzerland), 2021-02, Vol.10 (2), p.168
Main Authors: Yeh, Tsung-Jang, Chan, Leong-Perng, Tsai, Hui-Ting, Hsu, Chin-Mu, Cho, Shih-Feng, Pan, Mei-Ren, Liu, Yi-Chang, Huang, Chih-Jen, Wu, Che-Wei, Du, Jeng-Shiun, Wang, Hui-Ching
Format: Article
Language:English
Subjects:
Adverse events
Breast cancer
Cancer therapies
Chemoradiotherapy
Chemotherapy
Colorectal cancer
Disease
Enzymes
Head & neck cancer
HNSCC
Hypertension
Laboratories
Larynx
Lung cancer
Medical prognosis
Metastases
Metastasis
metronomic chemotherapy
Otolaryngology
Patients
Radiation therapy
Squamous cell carcinoma
Surgery
survival
Survival analysis
Tegafur
tegafur-uracil
Uracil
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aimed to demonstrate the outcomes of metronomic chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma (LA HNSCC). This was a retrospective study including 240 patients with LA HNSCC. After standard treatment, 96 patients were further treated with metronomic tegafur-uracil, and 144 patients were not. No statistical differences were found between both groups with regard to sex, clinical stage, or primary treatment choice. There were more hypopharyngeal cancers and more patients with poor clinicopathological features, including lymphovascular invasion, extranodal extension, and positive margins in the tegafur-uracil group. The median follow-up duration was 31.16 months. Overall survival (OS) was not reached in the tegafur-uracil group and was 54.1 months in the control group ( = 0.008). The median disease-free survival (DFS) was 54.5 months in the tegafur-uracil group and 34.4 months in the control group ( = 0.03). Neither group reached distant metastasis-free survival (DMFS, = 0.02). In patients with LA HNSCC, adding tegafur-uracil as metronomic chemotherapy after either curative surgery with adjuvant chemoradiotherapy or definitive concurrent chemoradiotherapy significantly improved the OS, DFS, and DMFS with tolerable adverse events.
ISSN:2079-7737
2079-7737
DOI:10.3390/biology10020168